BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28802253)

  • 1. The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer.
    Tran LNK; Kichenadasse G; Butler LM; Centenera MM; Morel KL; Ormsby RJ; Michael MZ; Lower KM; Sykes PJ
    Mol Cancer Ther; 2017 Dec; 16(12):2689-2700. PubMed ID: 28802253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth
    Tran LNK; Kichenadasse G; Morel KL; Lavranos TC; Klebe S; Lower KM; Ormsby RJ; Elliot DJ; Sykes PJ
    In Vivo; 2019; 33(1):99-108. PubMed ID: 30587609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.
    Tran LNK; Kichenadasse G; Sykes PJ
    Curr Cancer Drug Targets; 2019; 19(5):368-381. PubMed ID: 30039761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells.
    Wu W; Karelia D; Pramanik K; Amin SG; Sharma AK; Jiang C; Lu J
    Mol Carcinog; 2018 Aug; 57(8):1055-1066. PubMed ID: 29668110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
    Won SH; Lee HJ; Jeong SJ; Lü J; Kim SH
    Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
    Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
    Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
    Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F
    Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.
    Zhang X; Zhang X; Huang T; Geng J; Liu M; Zheng J
    Int J Clin Exp Pathol; 2015; 8(3):2823-8. PubMed ID: 26045790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
    Karelia DN; Kim S; Plano D; Sharma AK; Jiang C; Lu J
    Prostate; 2023 Jan; 83(1):16-29. PubMed ID: 35996318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
    Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
    Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
    Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
    Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emodin induces apoptosis in human prostate cancer cell LNCaP.
    Yu CX; Zhang XQ; Kang LD; Zhang PJ; Chen WW; Liu WW; Liu QW; Zhang JY
    Asian J Androl; 2008 Jul; 10(4):625-34. PubMed ID: 18478162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lipogenesis and induction of apoptosis by valproic acid in prostate cancer cells via the C/EBPα/SREBP-1 pathway.
    Pang B; Zhang J; Zhang X; Yuan J; Shi Y; Qiao L
    Acta Biochim Biophys Sin (Shanghai); 2021 Mar; 53(3):354-364. PubMed ID: 33471067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
    Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
    Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.
    Udayakumar TS; Stoyanova R; Shareef MM; Mu Z; Philip S; Burnstein KL; Pollack A
    Mol Cancer Ther; 2016 Jun; 15(6):1353-63. PubMed ID: 26944919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
    Li X; Li T; Chen D; Zhang P; Song Y; Zhu H; Xiao Y; Xing Y
    Oncol Rep; 2016 Jan; 35(1):584-92. PubMed ID: 26534764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer.
    Rokhlin OW; Guseva NV; Taghiyev AF; Glover RA; Cohen MB
    Cancer Biol Ther; 2010 Feb; 9(3):224-35. PubMed ID: 20023417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.